Asset profile
Trosunilimab
Monoclonal antibody
Evidence outlook · lead readout
NCT06032546 · Human Immuno-deficiency Virus (HIV) Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06032546: This trial was randomized, quadruple-blind, and placebo-controlled, and its primary measure (viral control without restarting antiretroviral therapy) is a recognized disease-relevant outcome for HIV. However, results have not been posted yet, and the six-arm combination design makes the overall picture more complex to interpret.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2030 (1)
January 2030 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access Research2031 (1)
October 2031 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.